BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mauro E, Garcia-Olveira L, Gadano A. End-stage liver disease: Management of hepatorenal syndrome. Liver Int 2021;41 Suppl 1:119-27. [PMID: 34155791 DOI: 10.1111/liv.14866] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Kaewput W, Thongprayoon C, Dumancas CY, Kanduri SR, Kovvuru K, Kaewput C, Pattharanitima P, Petnak T, Lertjitbanjong P, Boonpheng B, Wijarnpreecha K, Zabala Genovez JL, Vallabhajosyula S, Jadlowiec CC, Qureshi F, Cheungpasitporn W. In-hospital mortality of hepatorenal syndrome in the United States: Nationwide inpatient sample. World J Gastroenterol 2021; 27(45): 7831-7843 [PMID: 34963745 DOI: 10.3748/wjg.v27.i45.7831] [Reference Citation Analysis]
2 Yang W, Tao K, Zhang P, Chen X, Sun X, Li R. Maresin 1 protects against lipopolysaccharide/d-galactosamine-induced acute liver injury by inhibiting macrophage pyroptosis and inflammatory response. Biochem Pharmacol 2022;195:114863. [PMID: 34861244 DOI: 10.1016/j.bcp.2021.114863] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]